Anti-emetic prophylaxis for chemotherapy-induced nausea and vomiting without dexamethasone: a double-blind, phase 3 randomized controlled trial - CINV POD (ChemotherapyInduced Nausea and VomitingProphylaxis Omitting Dexamethasone).

Cancer Institute0 个研究点目标入组 350 人开始时间: 待定最近更新: 2023年2月6日

试验速览

暂无简介。

•1. Age between 18 to 80 years and diagnosed with cancer.
•2. Chemotherapy naÃ¯ve.
•3. Receiving single day Highly Emetogenic Chemotherapy.
•4. Absence of nausea or vomiting 24 hours before enrollment.
•5. Eastern Cooperative Oncology Group performance status of 0, 1, or 2.
•6. Adequate organ function as confirmed by laboratory investigations within 2 weeks
•[Aspartate transaminase (AST) and Alanine transaminase (ALT) within 5 times the
•upper limit of normal (ULN), serum bilirubin less than 2 mg/dL, serum creatinine
•within ULN].
•7. Hb more than 7 gms%, WBC more than 4000/cumm and platelets more than 100,000/cumm.
•8. No concurrent use of quinolone antibiotic therapy.
•9. No severe alcohol use disorder as defined by Diagnostic Statistical Manual of Mental
•Disorders, 5th Edition (DSM-5).
•10. Women enrolled in the trial need to have a negative pregnancy test within seven days
•of enrollment and continue to practice contraception during the study period.Â
•11. Written informed consent before enrollment.

•1.Pediatric patients (age less than 18 years)
•2.Patients receiving steroids as part of the chemotherapy regimen or needed as pre-medication for the prevention of allergic reactions. For eg: paclitaxel and carboplatin.
•3.Patients receiving multi-day chemotherapy in a chemotherapy block.
•4.Patients with brain metastasis.
•5.No abdominal radiotherapy.
•6.Patients in whom there are contraindications for corticosteroid use like uncontrolled diabetes mellitus, uncontrolled hypertension, and active peptic ulcer disease.
•7.History of allergy to any of the drugs used for anti-emetic prophylaxis.
•8.Treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone for 30 days before or during the protocol therapy.
•9.Known cardiac arrhythmia, uncontrolled congestive heart failure, or acute myocardial infarction within the previous six months.
•10.History of neurological disorders including seizures and stroke within the last 6 months.

发起方

Cancer Institute